0001708331
false
0001708331
2023-11-15
2023-11-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 15, 2023
Virpax Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40064 |
|
82-1510982 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
(Address of principal executive offices, including
zip code)
(610) 727-4597
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to
Section 12(b) of the Act:
Title of Each Class: |
|
Trading Symbol |
|
Name of Each Exchange on which Registered |
Common Stock, par value $0.00001 per share |
|
VRPX |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operation
and Financial Condition.
On November 15, 2023, Virpax Pharmaceuticals,
Inc., a Delaware corporation (the “Registrant”), issued a press release that included financial information for its quarter
ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and in the press
release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1
to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission
made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished with this Current Report on
Form 8-K:
Signature
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VIRPAX PHARMACEUTICALS, INC. |
|
|
|
Dated: November 16, 2023 |
By: |
/s/ Vinay Shah |
|
|
Vinay Shah |
|
|
Chief Financial Officer |
2
Exhibit 99.1
VIRPAX PHARMACEUTICALS
REPORTS 2023 THIRD QUARTER RESULTS
AND RECENT DEVELOPMENTS
BERWYN, PA, November
15, 2023 — Virpax® Pharmaceuticals, Inc. (“Virpax”
or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management,
post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results
for the three months ended September 30, 2023, and other recent developments.
“We recently announced
results from two preclinical studies for Probudur™, our lead product candidate for post operative pain, that demonstrated
significantly longer efficacy in animal models than the product currently on the market today. With these solid results, we believe we
are on track to file our Investigational New Drug (IND) Application and begin our Phase 2 trials
of Probudur in 2024 upon completion of a few ongoing and planned additional studies,” commented Anthony P. Mack, Chairman
and Chief Executive Officer of Virpax.
“Additionally,
following our pre-IND meeting with the FDA, we expect to submit an IND for Envelta™, our non-addictive pain product candidate
for acute and chronic pain, in mid-2024 and initiate first in human trials in 2024. We are grateful for the support and collaboration
from the National Institutes of Health (NIH) in the development of Envelta as a safe and effective alternative for opioids and are excited
to continue to advance this program with them.”
“Earlier this year,
we announced that we had hired two firms to assist us in developing licensing opportunities for both our Rx and OTC product candidates.
We have had strong interest from potential licensing partners and are encouraged by the current level of activity,” continued Mr.
Mack. “Finally, we have grant programs for each of our Rx product candidates as part of our non-dilutive funding strategy. We believe
this is an important validation of our assets and continue to pursue additional grant funding where we believe we have a strong chance
of winning the grant. Virpax continues to make progress across the board, and we look forward to sharing our results with all of our shareholders.”
RECENT DEVELOPMENTS
| ● | On October 31, 2023, Virpax announced
that it expects to submit an IND for Envelta in mid-2024 following review of comments made by the US Food and Drug Administration on the
Company’s Pre-IND submission. If successful, that would allow clinical trials to begin by the middle of 2024. Envelta is the Company’s
non-addictive pain product candidate for acute and chronic pain that is being funded under an in-kind grant from the National Center for
Advancing Translational Sciences (NCATS), part of the NIH. |
| ● | On October 12, 2023, Virpax announced
that the cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate
Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine formulation that is injected at the wound site,
has been extended to September of 2024. The USASIR is the U.S. Department of Defense’s primary laboratory for developing solutions
for trauma and critical care challenges in combat casualties. |
| ● | On October 2, 2023, the Company announced Gerald
W. Bruce has been appointed as President and CEO of Novvae™ Pharmaceuticals,
Virpax’s wholly-owned subsidiary focused solely on advancing the Company’s OTC pipeline. Mr. Bruce has over 30 years’
experience in the pharmaceutical and medical nutrition industries primarily in commercial strategy, sales, and marketing. |
| ● | On September 27, 2023, Virpax announced results
for two pre-clinical Probudur™ dose escalation studies. Results from the first study utilizing a planar incision model compared
Probudur to Exparel® and demonstrated three times longer efficacy for Probudur than Exparel. In the second study,
two different formulations at the same dose of Probudur were compared to Exparel in rat incision models and exhibited a four to five times
longer effect than the comparable product. |
| ● | On August 10,2023, Virpax announced that it filed a new provisional patent
application with the United States Patent and Trademark Office (USPTO) entitled “NSAID Formulation and Method” related to
its Epoladerm™ product candidate. Epoladerm is an over-the-counter diclofenac topical spray film that the Company is
developing for pain associated with Osteoarthritis. |
| ● | On July 24, 2023, Virpax rang
the Nasdaq closing bell. |
| ● | On July 13, 2023, Virpax announced that it had
filed a new provisional patent application with the USPTO entitled “Intranasal Delivery” related to its Envelta™ product
candidate. Envelta utilizes Molecular Envelope Technology (MET) for the delivery of Enkephalin intranasally with a delivery device which
propels the formulation into nose such that the enkephalin is delivered directly to the brain. |
THIRD QUARTER 2023 FINANCIAL RESULTS
General and administrative expenses were $4.6
million for the three months ended September 30, 2023, compared to $4.9 million for the same period in 2022. The decrease was primarily
due to lower legal defense costs related to litigation, net of litigation accrual, and was partially offset by an increase in salaries
and wages, board of directors’ fees, travel expenses, stock-based compensation, and professional fees.
Research and development expenses were $1.5 million
for the three months ended September 30, 2023, compared to $2.8 million for the same period in 2022. The decrease was primarily attributable
to decreases in preclinical activities for AnQlar, NobrXiol, and Epoladerm. This was partially offset by an increase in preclinical activity
related to Probudur.
The operating loss for the three months ended
September 30, 2023, was $6.1 million, compared to an operating loss of $7.7 million for the same period in 2022.
As of September 30, 2023, cash and cash equivalents
were $12.2 million, compared to $19.0 million as of December 31, 2022.
About Virpax Pharmaceuticals
Virpax is developing
branded, non-addictive pain management product candidates using its proprietary technologies to optimize and target drug delivery. Virpax
is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™
is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal
molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax
is also using its intranasal Molecular Envelope Technology (MET) to develop two other product candidates. PES200 is a product candidate
being developed to manage post-traumatic stress disorder (PTSD) and NobrXiol™ is a product candidate being developed for the nasal
delivery of a pharmaceutical grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax recently acquired global rights
to NobrXiol. Virpax is also seeking approval of two nonprescription product candidates: AnQlar™, which is being developed
to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is
a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please
visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.
Forward-Looking Statement
This press release contains
certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s planned clinical trials,
product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions.
These statements may
be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,”
“intend,” “plan,” “believe,” “estimate,” “potential,” “predict,”
“project,” “should,” “would” and similar expressions and the negatives of those terms and include
statements such as the Company being on track to file an Investigational New Drug (IND) Application and begin Phase 2 trials of Probudur
in 2024 upon completion of a few ongoing and planned additional studies, submitting an IND for Envelta in mid-2024 and initiating first
in human trials in 2024, pursuing additional grant funding where the Company believes it has a strong chance of winning the grant and
continuing to make progress across the board. These statements relate to future events or the Company’s financial performance and
involve known and unknown risks, uncertainties, and other factors, including the Company’s ability to successfully complete research
and further development, including reporting results from additional pre-IND studies in advance of entering the clinic in 2024, and commercialization
of Company drug candidates in current or future indications; the Company’s ability to obtain additional grant funding, the uncertainties
inherent in clinical testing; the Company’s ability to manage and successfully complete clinical trials and the research and development
efforts for multiple product candidates at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals
for the Company’s product candidates; the Company’s ability to protect its intellectual property; the loss of any executive
officers or key personnel or consultants and the ability of such executives to make valuable contributions to the Company; competition;
changes in the regulatory landscape or the imposition of regulations that affect the Company’s product candidates; the Company’s
ability to continue to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all, including the additional capital
which will be necessary to complete clinical trials that the Company plans to initiate; and other factors listed under “Risk Factors”
in our annual report on Form 10-K and quarterly reports on Form 10-Q that the Company files with the U.S. Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.
CONDENSED BALANCE SHEETS
| |
September 30,
2023 | | |
December 31,
2022 | |
| |
(Unaudited) | | |
(Audited) | |
ASSETS | |
| | |
| |
Current assets | |
| | |
| |
Cash | |
$ | 12,152,993 | | |
$ | 18,995,284 | |
Prepaid expenses and other current assets | |
| 885,394 | | |
| 678,365 | |
Total current assets | |
| 13,038,387 | | |
| 19,673,649 | |
Total assets | |
$ | 13,038,387 | | |
$ | 19,673,649 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ DEFICIT | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 1,532,723 | | |
$ | 1,094,590 | |
Estimated litigation liability | |
| 5,000,000 | | |
| 2,000,000 | |
Total current liabilities | |
| 6,532,723 | | |
| 3,094,590 | |
Total liabilities | |
| 6,532,723 | | |
| 3,094,590 | |
| |
| | | |
| | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Preferred stock, par value $0.00001, 10,000,000 shares authorized; no shares issued and outstanding as of both September 30, 2023 and December 31, 2022 | |
| — | | |
| — | |
Common stock, $0.00001 par value; 100,000,000 shares authorized, 11,714,284 shares issued and outstanding as of September 30, 2023 and December 31, 2022 | |
| 117 | | |
| 117 | |
Additional paid-in capital | |
| 61,487,973 | | |
| 60,933,569 | |
Accumulated deficit | |
| (54,982,426 | ) | |
| (44,354,627 | ) |
Total stockholders’ equity | |
| 6,505,664 | | |
| 16,579,059 | |
Total liabilities and stockholders’ equity | |
$ | 13,038,387 | | |
$ | 19,673,649 | |
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
| |
For the Three Months Ended
September 30, | | |
For the Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
OPERATING EXPENSES | |
| | |
| | |
| | |
| |
General and administrative (net of insurance reimbursement of $0 and $1,250,000 during the three and nine months ended September 30, 2023 - See Note 5) | |
$ | 4,619,519 | | |
$ | 4,910,039 | | |
$ | 6,983,670 | | |
$ | 9,338,070 | |
Research and development | |
| 1,495,619 | | |
| 2,805,103 | | |
| 4,022,020 | | |
| 9,404,980 | |
Total operating expenses | |
| 6,115,138 | | |
| 7,715,142 | | |
| 11,005,690 | | |
| 18,743,050 | |
Loss from operations | |
| (6,115,138 | ) | |
| (7,715,142 | ) | |
| (11,005,690 | ) | |
| (18,743,050 | ) |
| |
| | | |
| | | |
| | | |
| | |
OTHER INCOME | |
| | | |
| | | |
| | | |
| | |
Other income | |
| 120,640 | | |
| 73,252 | | |
| 377,891 | | |
| 79,443 | |
Loss before income taxes | |
| (5,994,498 | ) | |
| (7,641,890 | ) | |
| (10,627,799 | ) | |
| (18,663,607 | ) |
Income taxes | |
| — | | |
| — | | |
| — | | |
| — | |
Net loss | |
$ | (5,994,498 | ) | |
$ | (7,641,890 | ) | |
$ | (10,627,799 | ) | |
$ | (18,663,607 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted net loss per share | |
$ | (0.51 | ) | |
$ | (0.65 | ) | |
$ | (0.91 | ) | |
$ | (1.59 | ) |
Basic and diluted weighted average common stock outstanding | |
| 11,714,284 | | |
| 11,713,379 | | |
| 11,714,284 | | |
| 11,711,624 | |
CONDENSED
STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
For the Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES | |
| |
Net loss | |
$ | (10,627,799 | ) | |
$ | (18,663,607 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Stock-based compensation | |
| 554,404 | | |
| 606,758 | |
Change in operating assets and liabilities: | |
| | | |
| | |
Prepaid expenses and other current assets | |
| (207,029 | ) | |
| (342,706 | ) |
Accounts payable and accrued expenses | |
| 438,133 | | |
| 2,120,174 | |
Estimated litigation liability | |
| 3,000,000 | | |
| — | |
Net cash used in operating activities | |
| (6,842,291 | ) | |
| (16,279,381 | ) |
| |
| | | |
| | |
Net change in cash | |
| (6,842,291 | ) | |
| (16,279,381 | ) |
Cash, beginning of year | |
| 18,995,284 | | |
| 36,841,992 | |
Cash, end of year | |
$ | 12,152,993 | | |
$ | 20,562,611 | |
Contact:
Vinay Shah
Chief Financial Officer
vshah@virpaxpharma.com
610-727-4597
Or
Betsy Brod
Affinity Growth Advisors
betsy.brod@affinitygrowth.com
212-661-2231
7
v3.23.3
Cover
|
Nov. 15, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 15, 2023
|
Entity File Number |
001-40064
|
Entity Registrant Name |
Virpax Pharmaceuticals, Inc.
|
Entity Central Index Key |
0001708331
|
Entity Tax Identification Number |
82-1510982
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1055 Westlakes Drive
|
Entity Address, Address Line Two |
Suite 300
|
Entity Address, City or Town |
Berwyn
|
Entity Address, State or Province |
PA
|
Entity Address, Postal Zip Code |
19312
|
City Area Code |
610
|
Local Phone Number |
727-4597
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.00001 per share
|
Trading Symbol |
VRPX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Virpax Pharmaceuticals (NASDAQ:VRPX)
Historical Stock Chart
From Apr 2024 to May 2024
Virpax Pharmaceuticals (NASDAQ:VRPX)
Historical Stock Chart
From May 2023 to May 2024